Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

21.89 +0.09 (+0.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Catalyst Pharm Inc

< Previous 1 2 3 4 5 6 7 Next >
NASDAQ:CPRX, a growth stock which is not overvalued.
NASDAQ:CPRX is showing decent growth, but is still valued reasonably. 
Via Chartmill
Biotech Momentum Trades For The Q4 Rally
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. 
Via Talk Markets
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. 
Via Investor's Business Daily
NASDAQ:CPRX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Exploring the Growth Potential of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as It Nears a Breakout. 
Via Chartmill
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer. 
Via Investor's Business Daily
Looking for growth without the hefty price tag? Consider NASDAQ:CPRX.
While growth is established for CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), the stock's valuation remains reasonable. 
Via Chartmill
NASDAQ:CPRX is showing good growth, while it is not too expensive.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is not too expensive for the growth it is showing. 
Via Chartmill
Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock and is consolidating. 
Via Chartmill
The Latest Analyst Ratings For Catalyst Pharmaceuticals
Via Benzinga
A Biotech Breakout Will Be Led By Small Caps
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever. 
Via Talk Markets
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
Via Investor's Business Daily
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
Via Investor's Business Daily
Biohaven Stock Earns Relative Strength Rating Upgrade
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
Via Investor's Business Daily
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance. 
Via Investor's Business Daily
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
Via Benzinga
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
Via Benzinga
Investors should take notice of NASDAQ:CPRX—it offers a great deal for the fundamentals it presents.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), an undervalued stock with good fundamentals. 
Via Chartmill
NASDAQ:CPRX stands out as a growth opportunity that won't break the bank.
Don't overlook CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Immunome Stock Sees RS Rating Jump To 91
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91. 
Via Investor's Business Daily
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83. 
Via Investor's Business Daily
Top 3 Health Care Stocks That May Crash In August
Via Benzinga
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Top 3 Health Care Stocks You May Want To Dump This Quarter
Via Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. 
Via Investor's Business Daily
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
These two healthcare stocks may be deeply undervalued. 
Via The Motley Fool
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
Catalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year. 
Via Investor's Business Daily
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.